Cincinnati Children’s has been issued a US patent for the “Optimization and Individualization of Medication Selection and Dosing,” a technology that supports personalized dosing of psychiatric and pain medications.

The technology was invented by Cincinnati Children’s faculty Tracy Glauser, MD; Alexander Vinks, PharmD, PhD, FCP; and John Pestian, PhD, MBA and Richard Wenstrup, MD, now Chief Medical Officer at Myriad Genetics, Inc.

Cincinnati Children’s has licensed the technology to Assurex Health, which has developed pharmacogenomic tests for psychiatric, ADHD, and pain medications commercialized under the GeneSight® brand.

“Individualizing both the selection and dosing of medications will improve patient outcomes by providing objective, evidence-based information to tailor treatment programs,” said Tracy Glauser, MD, Associate Director, Cincinnati Children’s Research Foundation and lead inventor in a Dec. 2, 2013 announcement. “The issuance of this patent points to the importance of pharmacogenomic-directed prescribing and its potential to improve patient care in routine clinical practice.”

Learn more about the new patent.